Pharmafile Logo
Pharmafocus logo
Advanced Search

Alvotech

Showing 6 posts of 6 posts found.

Alvotech appoints Lisa Graver as CEO

February 3, 2026
Alvotech, CEO

Alvotech has announced the appointment of Lisa Graver as CEO, following the retirement of Róbert Wessman. Wessman served as Chairman …

Appointment

Alvotech biosimilar receives EC marketing approval

November 26, 2025
Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology

The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi (golimumab), which is used for …

News

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar

June 18, 2024
Sales and Marketing Advanz Pharma, Alvotech, Opthalmology, biosimilar

Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation of AVT06, Alvotech’s proposed biosimilar …

News

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

November 15, 2023
Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …

News
rasmus-web

Alvotech recruit new CEO from within

August 9, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alvotech, biotech, drugs, pharma, pharmaceutical

Alvotech, a biopharmaceutical company focusing on the development and manufacture of based in Reykjavik, Iceland, has replaced outgoing CEO, Eef …

Appointment
screen_shot_2014-03-18_at_08

Pharma manufacturing news in brief

March 18, 2014
Manufacturing and Production Aesica, Alvotech, Codexis/Intrexon, Pluristem, Updates from Bayer

 Bayer says it plans to invest more than €500 million to establish additional manufacturing capacity for its haemophilia drugs at …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026